Zentalis Pharmaceuticals, Inc.
ZNTLNasdaq
$5.11
↑ +11.8%Jul 17 close · end-of-day
Price
1Y↑ +267.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$359.0M
Enterprise Value
$147.3M
P/E
—
P/S
—
P/B
2.0
EV/EBITDA
—
PEG
—
FCF Yield
-35.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$124.1M
Free Cash Flow (TTM)
-$125.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-68.0%
ROIC
—
Debt / Equity
—
Net Cash
$211.8M
Return 1Y
+254.9%
Company profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
- CEO
- Kimberly L. Blackwell
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 160
- Headquarters
- California
- Website
- zentalis.com
Earnings
ZNTL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.50↓ -25.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $67.4M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$118.8M | -$216.5M | -$227.3M | -$299.5M | -$191.2M | -$152.8M |
| Net income | -$117.8M | -$158.7M | -$236.8M | -$292.3M | -$165.9M | -$137.1M |
| Diluted EPS | -$4.19 | -$3.72 | -$4.48 | -$4.47 | -$2.33 | -$1.91 |
| Operating cash flow | -$86.8M | -$154.1M | -$163.8M | -$207.8M | -$170.9M | -$125.2M |
| Free cash flow | -$87.6M | -$160.2M | -$166.3M | -$208.4M | -$171.1M | -$125.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -283.6% | — |
| Net margin | — | — | — | — | -246.0% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $26.9M | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$65.1M | -$51.4M | -$49.8M | -$45.6M | -$36.1M | -$33.7M | -$37.4M | -$37.9M |
| Net income | -$88.3M | -$40.2M | -$47.5M | -$48.3M | -$26.9M | -$26.7M | -$35.2M | -$35.4M |
| Diluted EPS | -$1.24 | -$0.56 | -$0.67 | -$0.67 | -$0.37 | -$0.37 | -$0.50 | -$0.50 |
| Operating cash flow | -$35.1M | -$44.0M | -$39.7M | -$32.6M | -$34.7M | -$27.0M | -$30.9M | -$33.0M |
| Free cash flow | -$35.3M | -$44.0M | -$39.7M | -$32.6M | -$34.7M | -$27.0M | -$30.9M | -$33.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -185.6% | — | — | — | — | — |
| Net margin | — | — | -176.8% | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.